Loading...
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara, Mairéad G Le, L Horgan, A Aspinall, A Burak, K Dhani, N Chen, E Sinaei, M Lo, G Kim, T
McNamara, Mairéad G
Le, L
Horgan, A
Aspinall, A
Burak, K
Dhani, N
Chen, E
Sinaei, M
Lo, G
Kim, T
Citations
Altmetric:
Abstract
Second-line treatment options in advanced hepatocellular carcinoma (HCC) are limited. Axitinib, a selective potent tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor VEGF) receptors 1, 2, and 3, merits exploration in HCC.
Description
Date
2015-01-06
Publisher
Collections
Files
Loading...
cncr.29227.pdf
Adobe PDF, 257.34 KB
Keywords
Type
Article
Citation
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. 2015: Cancer